Curve Therapeutics Announces Grant of US Patent

Southampton, UK, 31st March 2021. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces the grant of US Patent 10,962,549 describing novel Microcycles that inhibit both HIF-1 and HIF-2.

Curve originated from world-leading Microcycle® research conducted by Professor Tavassoli’s group in the Department of Chemistry at the University of Southampton, UK. The company is pioneering a game-changing, functional, drug discovery engine to generate higher quality functional hits and leads with the aim of discovering first-in-class therapeutics against challenging therapeutic targets